ArticleOphthalmic epidemiology2022
Association of Systemic Inflammatory Factors with Progression to Advanced Age-related Macular Degeneration.
Article in Ophthalmic epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- C-reactive protein dissociation drives choroidal neovascularization in age-related macular degeneration.Scientific reports · 2025Article
- Heterochronic parabiosis uncovers AdipoR1 as a critical player in retinal rejuvenation.Science advances · 2025Article
- Association of systemic inflammatory biomarkers with ocular disease: a large population-based cross-sectional study.European journal of medical research · 2025Article
- Red blood cell distribution width-to-albumin ratio and its association with age-related macular degeneration: a population-based cross-sectional study.Frontiers in medicine · 2025Article
- Risk of progression in intermediate age-related macular degeneration among patients using systemic beta-blockers.Frontiers in ophthalmology · 2025Article
- Systemic C-reactive protein levels in patients with geographic atrophy stratified by sex.International journal of ophthalmology · 2025Article
- Adverse effects of CXCR2 deficiency in mice reared under non-gnotobiotic conditions.Scientific reports · 2024Article
- Association Between Quantitative and Qualitative Imaging Biomarkers and Geographic Atrophy Growth Rate.American journal of ophthalmology · 2024Article
- A comprehensive genetic map of cytokine responses in Lyme borreliosis.Nature communications · 2024Article
- The identification of signature genes and their relationship with immune cell infiltration in age-related macular degeneration.Molecular biology reports · 2024Article
- Elevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy.Frontiers in ophthalmology · 2024Article
- Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration.Ophthalmology and therapy · 2023Review
- Interleukin-4 Plasma Levels Stratified by Sex in Intermediate Age-Related Macular Degeneration and Geographic Atrophy.Translational vision science & technology · 2023Article
- Low Vision Referral Patterns in Intermediate Age-Related Macular Degeneration.Current eye research · 2022Article
- HBEGF-TNF induce a complex outer retinal pathology with photoreceptor cell extrusion in human organoids.Nature communications · 2022Article
- Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.Acta ophthalmologica · 2022Article
- Sex Differences in RANTES (CCL5) in Patients With Intermediate Age-Related Macular Degeneration (AMD) and Controls With no AMD.Translational vision science & technology · 2022Article
- Pro-Inflammatory diet accounts for higher prevalence of retinopathy in diabetes participants rather than normal glucose and prediabetes: Results from NHANES, 2005-2008.Frontiers in nutrition · 2022Article
- Osteoarthritis Is Associated With an Increased Risk of Age-Related Macular Degeneration: A Population-Based Longitudinal Follow-Up Study.Frontiers in medicine · 2022Article
- Increased Systemic C-Reactive Protein Is Associated With Choroidal Thinning in Intermediate Age-Related Macular Degeneration.Translational vision science & technology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeAge-related macular degeneration (AMD) is a leading cause of vision loss in the elderly. The role of systemic inflammation in AMD remains unclear specifically in patients with intermediate AMD (iAMD). We sought to determine whether systemic inflammation was associated with future iAMD progression.
methodsCombinations of 27 circulating inflammatory markers including complement factors, cytokines, chemokines, and high-sensitivity C-reactive protein (hsCRP) were evaluated in iAMD patients recruited into a Colorado AMD registry. Systemic inflammatory markers were combined using principal component analysis. Risk factors for AMD progression were evaluated using Cox regression models.
resultsThis study included 99 subjects with iAMD, 21 of which progressed to advanced AMD. Two principal components (PCs) were identified that contributed to the risk of progression to advanced AMD, after adjusting for age and bilateral reticular pseudodrusen. The strongest associated PC was explained largely by the pro-inflammatory cytokine TNFα and the anti-inflammatory IL1ra antagonist of IL1. The additional PC was largely explained by IL6, IL8, C3 and factor D in the positive direction and CRP, MCP1, factor B and factor I in the negative direction.
conclusionWhen evaluated through multivariate analyses, combinations of biomarkers distinguished patients who did and did not progress to future advanced AMD. Increased risk could result from different combinations of analyte levels indicating a complex relationship rather than a simple increase in a few markers. This suggests that studying systemic inflammation in iAMD can provide insights into early pathologic events and potentially identify patients at highest risk for the development of severe AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.